

# **Data Sheet**

Target: Apoptosis; Bacterial; HSV; PKC

Pathway: Anti-infection; Apoptosis; Epigenetics; TGF-beta/Smad

**Solubility:** DMSO :  $\geq$  100 mg/mL;H<sub>2</sub>O :  $\geq$  100 mg/mL

624.59

## **BIOLOGICAL ACTIVITY:**

**Molecular Weight:** 

Verbascoside is isolated from *Acanthus mollis*, acts as an ATP-competitive inhibitor of **PKC**, with an **IC**<sub>50</sub> of 25  $\mu$ M, and has antitumor, anti-inflammatory and antineuropathic pain activity. IC50 & Target:IC50: 25  $\mu$ M (PKC)<sup>[1]</sup> *In Vitro*: Verbascoside acts as an ATP-competitive inhibitor of PKC, with an IC<sub>50</sub> of 25  $\mu$ M. Verbascoside shows K<sub>i</sub>s of 22 and 28  $\mu$ M with respect to ATP and histone, respectively. Verbascoside has potent antitumor activity against L-1210 cells, with an IC<sub>50</sub> of 13  $\mu$ M<sup>[1]</sup>. Verbascoside (5, 10  $\mu$ M) suppresses 2,4-dinitrochlorobenzene (DNCB)-induced T cell costimulatory factors CD86 and CD54, proinflammatory cytokines, and NFκB pathway activation in THP-1 cells<sup>[2]</sup>. *In Vivo*: Verbascoside (1%) reduces the overall scratching behavior incidence as well as the severity of the skin lesions in 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD) mice model. Verbascoside also blocks DNCB-induced expression of proinflammatory cytokine TNF- $\alpha$ , IL-6, and IL-4 mRNA in skin lesions<sup>[2]</sup>. Verbascoside (50, 100 mg/kg, i.p.) does not modify chronic constriction injury (CCI)-induced cold allodynia. Verbascoside (200 mg/kg, i.p.) decreases hypersensitivity to cold stimulus, acetone, on day 3 in rats. Verbascoside also significantly reduces behavioral changes associated with neuropathy. Moreover, Verbascoside decreases Bax and increases Bcl-2 on day 3<sup>[3]</sup>.

## PROTOCOL (Extracted from published papers and Only for reference)

**Cell Assay:** Verbascoside is dissolved in DMSO<sup>[1]</sup>.<sup>[1]</sup>The lymphocytic mouse **leukemia L1210 cells** (ATCC, CCL 219) are plated sparsely at **10<sup>4</sup> cells per well** in 24-well cluster plates in Dulbecco's modified Eagle medium containing 10% fetal calf serum, 4 mM glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin sulfate, and **Verbascoside (solubilized in DMSO)**. After a 2-day incubation period at 37°C in a humidified atmosphere (5% CO<sub>2</sub> in air), growth is monitored by counting cell numbers in a Coulter-counter. IC<sub>50</sub> values are calculated on the basis of the linear regression lines established for each compound tested<sup>[1]</sup>.

Animal Administration: [2] Rats[2]

To induce **atopic dermatitis** (AD)-like symptoms, 2,4-dinitrochlorobenzene (DNCB) is used. Briefly, the dorsal hair of the **mice** is removed using an electronic clipper 2 days before DNCB treatment. An application of 200 µL of 1% DNCB (in acetone:olive oil = 4:1) is made to the shaved dorsal skin for sensitization. The repeated challenge is performed on the same site with 0.2% DNCB once every 3 days for about 2 weeks. The mice are divided into 4 groups (n = 6 per group): (1) vehicle-treated controls, (2) DNCB-treated only, (3) **1% Verbascoside (in acetone:olive oil 4:1)**-treated only, and (4) DNCB + 1% Verbascoside-treated group<sup>[2]</sup>.

#### References:

[1]. Herbert JM, et al. Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C. J Nat Prod. 1991 Nov-Dec;54(6):1595-600.

Page 1 of 2 www.ChemScene.com

[2]. Li Y, et al. Verbascoside Alleviates Atopic Dermatitis-Like Symptoms in Mice via Its Potent Anti-Inflammatory Effect. Int Arch Allergy Immunol. 2018;175(4):220-230.

[3]. Amin B, et al. The Effect of Verbascoside in Neuropathic Pain Induced by Chronic Constriction Injury in Rats. Phytother Res. 2016 Jan;30(1):128-35.

## **CAIndexNames:**

 $\beta\text{-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)-ethyl 3-O-(6-deoxy-$\alpha$-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]}$ 

# **SMILES:**

O[C@@H]([C@H](OCCC1=CC(O)=C(O)C=C1)O2)[C@H]([C@@H]([C@H]2CO)OC(/C=C/C3=CC(O)=C(O)C=C3)=O)O[C@@](O[C@@H](C)[C@H](O)[CWH](O)[C

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.ChemScene.com